Incyte announced that the Japanese Ministry of Health, Labour and Welfare has approved Pemazyre®, a selective fibroblast growth factor receptor inhibitor, for the treatment of myeloid/lymphoid neoplasms with FGFR1 fusion.
Incyte announced that the Japanese Ministry of Health, Labour and Welfare has approved Pemazyre®, a selective fibroblast growth factor receptor inhibitor, for the treatment of myeloid/lymphoid neoplasms with FGFR1 fusion.